SA
NVCR icon

Scarborough Advisors’s NovoCure NVCR Stock Holding History

Scarborough Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100
Closed -$1.09K – 498
2026
Q1 		$1.09K Buy
+100
New +$1.25K ﹤0.01% 636

Other funds holding NVCR

BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return
CMF
Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
SIC
SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return

Scarborough Advisors's NVCR Position: Q2 2026 in Review

Scarborough Advisors sold out of NovoCure (NVCR) in Q2 2026, closing a stake of 100 shares — an estimated $1.09K sold.

Scarborough Advisors first reported a position in NVCR in Q1 2026 and held it in 1 quarter. The position peaked at $1.09K in Q1 2026. 25 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Scarborough Advisors reported no remaining NovoCure position as of Q2 2026 after selling out during the quarter.
  • Scarborough Advisors sold 100 NovoCure shares in Q2 2026, an estimated $1.09K.
  • Scarborough Advisors first reported a position in NovoCure in Q1 2026 and held it in 1 quarter.
  • Scarborough Advisors's NovoCure position peaked at $1.09K in Q1 2026.
  • 25 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Scarborough Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.